3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
ribociclib
2
Specimen Handling
2
tucatinib
1
trastuzumab biosimilar HLX02
1
pertuzumab
1
pembrolizumab
1
exemestane
1
durvalumab
1
Watchful Waiting
1
Trastuzumab
1
Taxes
1
Paclitaxel
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Observation
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Immunoglobulin G
1
Genetic Testing
1
Fulvestrant
1
Drug Therapy
1
Doxorubicin
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Carboplatin
1
Biopsy
1
Anastrozole
1
2C4 antibody
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Anatomic Stage II Breast Cancer AJCC v8
×
Ado-Trastuzumab Emtansine
×
30 days
×
Clear all
No trials found.